AstraZeneca cashes in on sale of dental unit
AstraZeneca is selling its dental local anesthetics business, whichincludes products such as Xylocaine (lidocaine), Citanest (prilocaine) and Polocaine/Carbocaine (mepivacaine hydrochloride), to the US firm Dentsply International in a deal worth $136.5 million. AstraZeneca will also receive future royalty payments for Oraqix, its new dental gel for scaling and root planning, which is currently in Phase III clinical trials.
The Anglo-Swedish group's executive director, Ake Stavling, said that following a strategic review of its product portfolio, it believes that its dental range of anesthetics "can be better coordinated and marketed by a dedicated dental products company." The range accounts for about 7% of AstraZeneca's total anesthetic portfolio sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze